In a 60-year-old woman with triple-negative breast cancer (TNBC) whose tumor demonstrates low Ki-67 and 100% androgen receptor (AR) positivity: (1) if she has early-stage disease (T2N0) and has undergone surgical resection, would there be a role for adjuvant androgen receptor–targeted therapy with enzalutamide or bicalutamide; and (2) if she instead presented with metastatic disease, how — if at all — would you incorporate anti-androgen therapy into her treatment regimen?